All Clinical Trials

A listing of 23128 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Trials

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Study of Factors Regulating Mast Cell Proliferation

NCT00044122

Recruiting

This study will examine growth factors that promote and inhibit mast cell proliferation resulting in mastocytosis, a disease of excessive mast cells in the body. These cells can release chemicals that cause itching, blisters, flushing, bone pain and abdominal pain. Patients up to 80 years of age with mastocytosis may be eligible for this 1-day study. Participants will have one visit at NIH lasting up to 8 hours, during which they will undergo the following tests and procedures: * Medical histo... Read More

Gender:

ALL

Ages:

Between 1 day and 80 years

Trial Updated:

06/24/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Mastocytosis, Monoclonal, Bone Marrow, Tryptase

Learn More ›

Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System

NCT00794352

Recruiting

Inflammatory or degenerative diseases of the brain and spinal cord, such as multiple sclerosis, may be related to problems with an individual s immune system. However, more information is needed on the ways in which the cells of the immune system interact with the central nervous system (CNS). This study will compare tests performed on both healthy volunteers and individuals who have signs or symptoms of immune-related damage to their CNS. This study will include two groups of subjects at least... Read More

Gender:

ALL

Ages:

Between 1 month and 99 years

Trial Updated:

06/24/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Central Nervous System Disease, Multiple Sclerosis

Learn More ›

Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database

NCT02107989

Recruiting

Objectives: The overall study objective is to compare the sensitivities and specificities of morphometric analysis techniques using structural MRI images based on pre- and postsurgical localization of epileptic foci in patients undergoing presurgical evaluation for medically refractory epilepsy. To carry out these analyses, we aim to establish an age-stratified normative imaging database using healthy volunteers. Additional objectives are to identify abnormal networks in these patients using resting state fMRI/EEG and MEG/EEG, and to use language and memory fMRI tasks to examine the effects of epileptogenic zones and surgery on cognitive function and the networks associated with these functions. Study population: 300 adults and children (age 8 and older) with uncontrolled focal epilepsy, and 200 age-stratified healthy volunteers. Design: A retrospective and prospective natural history study. Research procedures for patients in this study include neuropsychological testing and 1-4 MRI sessions during presurgical evaluation and an additional 1-3 MRI sessions and neuropsychological testing approximately 12 months post-operatively. Research testing (such as research neuropsychological tests or MRI scanning sequences) will be done during a visit for clinical testing whenever possible, likely reducing the number of required visits. Patients will also have optional MEG and 7T structural imaging. Data will also be obtained from patients who have already undergone epilepsy surgery if they had procedures as outlined in the protocol and are willing to share the data. Healthy volunteers will receive a subset of the pre-operative procedures for patients, requiring at least 3 visits. In order to ensure adequate data acquisition, subjects may be re-scanned up to three times for the portions of the study in which they participated, possibly requiring additional visits. Outcome measures: The main outcomes will be establishment of normative values for morphometric analysis methods in age-stratified normal controls, and comparison of the sensitivity and specificity of these measures to pre- and postsurgical localization of the epileptogenic zone. Secondary outcome measures will include determination of the sensitivity and specificity of source localization using MEG/EEG and resting state fMRI/EEG, and to evaluate changes in activation during rest, as well as language and memory fMRI tasks in patients pre- and postsurgically, to examine the effects of epileptogenic zones and surgery on cognitive function and the networks underlying these functions. ... Read Less

Gender:

ALL

Ages:

Between 8 years and 120 years

Trial Updated:

06/24/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Epilepsy

Learn More ›

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

NCT04840589

Recruiting

This phase I/Ib trial is to find out the best dose, possible benefits and/or side effects of BET bromodomain inhibitor ZEN-3694 (ZEN003694) when given in combination with nivolumab with or without ipilimumab in treating patients with solid tumors. ZEN003694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/24/2025

Locations: National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland +6 locations

Conditions: Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma, Refractory Ovarian Carcinoma

Learn More ›

Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians

NCT05440929

Recruiting

I this qualitative study, Investigators will conduct semi-structured interviews with clinicians that are involved in the care of patients with breast cancer to evaluate the acceptability, appropriateness, and feasibility/usability of a metastatic breast cancer-specific prognostic tool. These interviews will be conducted by the UNC CHAI Core and will continue until thematic saturation (estimated 10 participants). The investigators will code the qualitative data using emerging themes, guided by a... Read More

Gender:

ALL

Ages:

All

Trial Updated:

06/24/2025

Locations: University of North Carolina, Chapel Hill, North Carolina

Conditions: Metastatic Breast Cancer, End of Life

Learn More ›

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

NCT06005493

Recruiting

This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/24/2025

Locations: Research Site, Jacksonville, Florida +24 locations

Conditions: Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma

Learn More ›

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376

Recruiting

The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/24/2025

Locations: Research Site, Alabaster, Alabama +317 locations

Research Site, Alabaster, Alabama

Research Site, Phoenix, Arizona

Research Site, Loma Linda, California

Research Site, Los Angeles, California

Research Site, Northridge, California

Research Site, Orange, California

Research Site, San Diego, California

Research Site, San Francisco, California

Research Site, Stanford, California

Research Site, Torrance, California

Research Site, Aurora, Colorado

Research Site, Bay Pines, Florida

Research Site, Miami, Florida

Research Site, Orlando, Florida

Research Site, Acworth, Georgia

Research Site, Lawrenceville, Georgia

Research Site, Iowa City, Iowa

Research Site, New Orleans, Louisiana

Research Site, Shreveport, Louisiana

Research Site, Augusta, Maine

Research Site, Boston, Massachusetts

Research Site, Pontiac, Michigan

Research Site, Minneapolis, Minnesota

Research Site, Kansas City, Missouri

Research Site, Saint Peters, Missouri

Research Site, North Las Vegas, Nevada

Research Site, Albany, New York

Research Site, Bronx, New York

Research Site, East Setauket, New York

Research Site, New York, New York

Research Site, Columbus, Ohio

Research Site, Charleston, South Carolina

Research Site, Knoxville, Tennessee

Research Site, Arlington, Texas

Research Site, Houston, Texas

Research Site, San Antonio, Texas

Research Site, Shenandoah, Texas

Research Site, Charlottesville, Virginia

Research Site, Milwaukee, Wisconsin

Research Site, Buenos Aires, Not set

Research Site, Ciudad Autonoma Bs As, Not set

Research Site, Cordoba, Not set

Research Site, Florencio Varela, Not set

Research Site, La Plata, Not set

Research Site, Rosario, Not set

Research Site, San Luis, Not set

Research Site, Camperdown, Not set

Research Site, Canberra, Not set

Research Site, Clayton, Not set

Research Site, Concord, Not set

Research Site, Herston, Not set

Research Site, Liverpool, Not set

Research Site, Parkville, Not set

Research Site, Perth, Not set

Research Site, Southport, Not set

Research Site, St Albans, Not set

Research Site, Graz, Not set

Research Site, Innsbruck, Not set

Research Site, Linz, Not set

Research Site, Brussels, Not set

Research Site, Edegem, Not set

Research Site, Leuven, Not set

Research Site, Liège, Not set

Research Site, Roeselare, Not set

Research Site, Belo Horizonte, Not set

Research Site, Botucatu, Not set

Research Site, Curitiba, Not set

Research Site, Fortaleza, Not set

Research Site, Recife, Not set

Research Site, Ribeirão Preto, Not set

Research Site, S.J. Do Rio Preto, Not set

Research Site, Salvador, Not set

Research Site, São Paulo, Not set

Research Site, Winnipeg, Manitoba

Research Site, London, Ontario

Research Site, Ottawa, Ontario

Research Site, Toronto, Ontario

Research Site, Araucania, Not set

Research Site, Providencia, Not set

Research Site, Santiago, Not set

Research Site, Valdivia, Not set

Research Site, Baotou, Not set

Research Site, Beijing, Not set

Research Site, Changsha, Not set

Research Site, Changzhou, Not set

Research Site, Chengdu, Not set

Research Site, Chongqing, Not set

Research Site, Guangzhou, Not set

Research Site, Hangzhou, Not set

Research Site, Jinan, Not set

Research Site, Jinhua, Not set

Research Site, Lanzhou, Not set

Research Site, Luoyang, Not set

Research Site, Nanchang, Not set

Research Site, Nanjing, Not set

Research Site, Ningbo, Not set

Research Site, Qingdao, Not set

Research Site, Shanghai, Not set

Research Site, Shenyang, Not set

Research Site, Shenzhen, Not set

Research Site, Urumqi, Not set

Research Site, Wuhan, Not set

Research Site, Wuxi, Not set

Research Site, Xian, Not set

Research Site, Yantai, Not set

Research Site, Yibin, Not set

Research Site, Yinchuan, Not set

Research Site, Zhanjiang, Not set

Research Site, Zhengzhou, Not set

Research Site, Zhongshan, Not set

Research Site, Barranquilla, Not set

Research Site, Bogota, Not set

Research Site, Cali, Not set

Research Site, Manizales, Not set

Research Site, Medellín, Not set

Research Site, Rionegro, Not set

Research Site, Nový Jičín, Not set

Research Site, Praha 2, Not set

Research Site, Praha 4, Not set

Research Site, Amiens, Not set

Research Site, Bayonne, Not set

Research Site, Brest Cedex, Not set

Research Site, Chambéry, Not set

Research Site, Clermont Ferrand, Not set

Research Site, Le Kremlin-Bicêtre, Not set

Research Site, Marseille, Not set

Research Site, Nantes, Not set

Research Site, Nice, Not set

Research Site, Paris, Not set

Research Site, Saint-Priest-en-Jarez, Not set

Research Site, Strasbourg, Not set

Research Site, Toulouse, Not set

Research Site, Aachen, Not set

Research Site, Berlin, Not set

Research Site, Erlangen, Not set

Research Site, Essen, Not set

Research Site, Greifswald, Not set

Research Site, Hannover, Not set

Research Site, Konstanz, Not set

Research Site, Köln, Not set

Research Site, Mainz, Not set

Research Site, München, Not set

Research Site, Villingen-Schwenningen, Not set

Research Site, Athens, Not set

Research Site, Heraclion, Not set

Research Site, Patras, Not set

Research Site, Thessaloniki, Not set

Research Site, Hong Kong, Not set

Research Site, Lai Chi Kok, Not set

Research Site, Shatin, Not set

Research Site, Budapest, Not set

Research Site, Miskolc, Not set

Research Site, Haifa, Not set

Research Site, Jerusalem, Not set

Research Site, Nazareth, Not set

Research Site, Petah Tikva, Not set

Research Site, Tel Aviv, Not set

Research Site, Agrigento, Not set

Research Site, Bari, Not set

Research Site, Bologna, Not set

Research Site, Brescia, Not set

Research Site, Cagliari, Not set

Research Site, Firenze, Not set

Research Site, Milano, Not set

Research Site, Padova, Not set

Research Site, Parma, Not set

Research Site, Piacenza, Not set

Research Site, Torino, Not set

Research Site, Torrette, Not set

Research Site, Verona, Not set

Research Site, Ashikaga, Not set

Research Site, Bunkyo-ku, Not set

Research Site, Chiba-shi, Not set

Research Site, Fukuoka-shi, Not set

Research Site, Kamakura, Not set

Research Site, Kasugai-shi, Not set

Research Site, Kitakyushu-shi, Not set

Research Site, Kobe-shi, Not set

Research Site, Matsumoto-shi, Not set

Research Site, Matsuyama-shi, Not set

Research Site, Nagoya, Not set

Research Site, Osaka-shi, Not set

Research Site, Sapporo-shi, Not set

Research Site, Toyota-Shi, Not set

Research Site, Urayasu-shi, Not set

Research Site, Anyang-si, Not set

Research Site, Busan, Not set

Research Site, Deagu, Not set

Research Site, Gwangju, Not set

Research Site, Gyeonggi-do, Not set

Research Site, Seoul, Not set

Research Site, Suwon-si, Not set

Research Site, Ipoh, Not set

Research Site, Johor Bahru, Not set

Research Site, Kuala Lumpur, Not set

Research Site, Seremban, Not set

Research Site, Taiping, Not set

Research Site, Chihuahua, Not set

Research Site, Culiacan, Not set

Research Site, Guadalajara, Not set

Research Site, Juriquilla, Not set

Research Site, Mexico, Not set

Research Site, Zapopan, Not set

Research Site, Amsterdam, Not set

Research Site, Groningen, Not set

Research Site, Nijmegen, Not set

Research Site, Rotterdam, Not set

Research Site, Białystok, Not set

Research Site, Kraków, Not set

Research Site, Lublin, Not set

Research Site, Olsztyn, Not set

Research Site, Poznań, Not set

Research Site, Szczecin, Not set

Research Site, Warszawa, Not set

Research Site, Łódź, Not set

Research Site, Braga, Not set

Research Site, Funchal, Not set

Research Site, Lisbon, Not set

Research Site, Porto, Not set

Research Site, Torres Novas, Not set

Research Site, Bucuresti, Not set

Research Site, Cluj Napoca, Not set

Research Site, Timisoara, Not set

Research Site, Dammam, Not set

Research Site, Jeddah, Not set

Research Site, Riyadh, Not set

Research Site, Banská Bystrica, Not set

Research Site, Bratislava, Not set

Research Site, Košice, Not set

Research Site, Martin, Not set

Research Site, Alcalá de Henares, Not set

Research Site, La Coruña, Not set

Research Site, Lérida, Not set

Research Site, Madrid, Not set

Research Site, Murcia, Not set

Research Site, Málaga, Not set

Research Site, Oviedo, Not set

Research Site, Sant Joan Despí, Not set

Research Site, Sevilla, Not set

Research Site, Tarragona, Not set

Research Site, Valencia, Not set

Research Site, Zaragoza, Not set

Research Site, Kaohsiung City, Not set

Research Site, Kaohsiung, Not set

Research Site, New Taipei City, Not set

Research Site, Taichung City, Not set

Research Site, Taichung, Not set

Research Site, Tainan City, Not set

Research Site, Taipei, Not set

Research Site, Taoyuan City, Not set

Research Site, Bangkok, Not set

Research Site, Chaingmai, Not set

Research Site, Khlong Luang, Not set

Research Site, Khon Kaen, Not set

Research Site, Ankara, Not set

Research Site, Bursa, Not set

Research Site, Istanbul, Not set

Research Site, Kahramanmaras, Not set

Research Site, Kayseri, Not set

Research Site, Kocaeli, Not set

Research Site, Konya, Not set

Research Site, Pamukkale, Not set

Research Site, Cambridge, Not set

Research Site, Doncaster, Not set

Research Site, Dundee, Not set

Research Site, Leicester, Not set

Research Site, London, Not set

Research Site, Reading, Not set

Research Site, Salford, Not set

Research Site, Stevenage, Not set

Conditions: Immunoglobulin A Nephropathy, IgAN

Learn More ›

Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

NCT06568042

Recruiting

The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee. Participation may last up to 30 weeks including screening.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/24/2025

Locations: MD First Research - Chandler, Chandler, Arizona +80 locations

MD First Research - Chandler, Chandler, Arizona

HOPE Research Institute, Phoenix, Arizona

Neuro-Pain Medical Center, Fresno, California

Alpine Clinical Research Center, Boulder, Colorado

Accel Research Sites - St. Pete-Largo Clinical Research Unit, Largo, Florida

Design Neuroscience Center, Miami Lakes, Florida

Conquest Research - Orlando, Orlando, Florida

Charter Research - Lady Lake, The Villages, Florida

Encore Medical Research - Weston, Weston, Florida

Conquest Research, Winter Park, Florida

Integrated Clinical Trial Services, Inc., West Des Moines, Iowa

Lucida Clinical Trials, New Bedford, Massachusetts

SKY Integrative Medical Center/SKYCRNG, Ridgeland, Mississippi

StudyMetrix Research, Saint Peters, Missouri

Mid Hudson Medical Research, New Windsor, New York

University of Rochester Medical Center, Rochester, New York

Asheville Neurology Specialists, PA, Asheville, North Carolina

Center for Clinical Research, Winston-Salem, North Carolina

Neurology Diagnostics, Inc., Dayton, Ohio

New Phase Research and Development, Knoxville, Tennessee

Cedar Health Research, Dallas, Texas

Biopharma Informatic, LLC, Houston, Texas

Clinical Trial Network, Houston, Texas

Northwest Clinical Research Center, Bellevue, Washington

OCT Research ULC, Kelowna, British Columbia

Richmond Clinical Trials, Richmond, British Columbia

Med Trust Research, Courtice, Ontario

Dawson Clinical Research Inc., Guelph, Ontario

Premier Clinical Trial Network, Hamilton, Ontario

Bluewater Clinical Research Group Inc., Sarnia, Ontario

Genge Partners, Montreal, Quebec

MUDr. Alena Vachova, Ceske Budejovice, Jihočeský Kraj

MUDr. Miroslav Koliba s.r.o., Ostrava, Ostrava Město

NEUROS s.r.o., Pilsen, Plzeň-město

Milan Kvapil s.r.o., Diabetologicka ambulance, Praha, Praha 4

Praglandia s.r.o, Praha 5, Not set

Studienzentrum Dr. Bischof GmbH, Boeblingen, Baden-Württemberg

Studienzentrum Nord-West, Westerstede, Niedersachsen

ZNS Siegen, Siegen, Nordrhein-Westfalen

Universitaetsklinikum Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein

emovis GmbH, Berlin, Not set

Kamezawa Clinic, Kasugai, Aichi

Kojunkai Daido Hospital, Nagoya, Aichi

Kikuchi Naika Clinic, Maebashi, Gunma

Chugoku Central Hospital, Fukuyama-shi, Hiroshima

Nishinomiya Municipal Central Hospital, Nishinomiya, Hyogo

Mito Medical Center, Higashiibaraki, Ibaraki

Aizawa Hospital, Matsumoto, Nagano

Asama General Hospital, Saku, Nagano

Rinku General Medical Center, Izumisano, Osaka

Saga-Ken Medical Centre Koseikan, Saga-shi, Saga

St. Luke's International Hospital, Chuo-ku, Tokyo

The Cancer Institute Hospital of JFCR, Koto, Tokyo

Medical Corporation Sato Medical clinic, Ootaku, Tokyo

Tokyo Shinagawa Hospital, Shinagawa-ku, Tokyo

Sagara Hospital, Kagoshima, Not set

Fujigaki Clinic, Oita, Not set

Minamiosaka Hospital, Osaka, Not set

Niwa Family Clinic, Tokyo, Not set

Chosun University Hospital, Gwangju, Kwangju-Kwangyǒkshi

Seoul National University Hospital, Seoul, Seoul-teukbyeolsi [Seoul]

Severance Hospital, Yonsei University Health System, Seoul, Seoul-teukbyeolsi [Seoul]

Konkuk University Medical Center, Seoul, Seoul-teukbyeolsi [Seoul]

Samsung Medical Center, Seoul, Seoul-teukbyeolsi [Seoul]

The Catholic Univ. of Korea Seoul St. Mary's Hospital, Seoul, Seoul-teukbyeolsi [Seoul]

Grupo Medico Camino Sc, Mexico City, Distrito Federal

Centro de Investigación Clínica y Medicina Traslacional (CIMeT), Guadalajara, Jalisco

Cicmex Centro de Investigación Clínica de México, Morelia, Michoacán

Investigación Clínica Cuernavaca, S.C., Cuernavaca, Morelos

Centro de Investigacion Clinica de Oaxaca, Oaxaca de Juarez, Oaxaca

Health Pharma Querétaro, Juriquilla, Querétaro

Medical Care and Research SA de CV, Merida, Yucatán

Scientia Investigacion Clinica S.C., Chihuahua, Not set

Centrum Medyczne NEUROMED, Bydgoszcz, Kujawsko-pomorskie

MICS Centrum Medyczne Warszawa, Warszawa, Mazowieckie

Diamond Clinic, Krakow, Małopolskie

Podlaskie Centrum Psychogeriatrii, Białystok, Podlaskie

Centrum Badan Klinicznych PI-House sp. z o.o., Gdansk, Pomorskie

Nzoz Neuro-Kard Ilkowski i Partnerzy SPL, Poznan, Wielkopolskie

Santa Familia PTG Lodz, Lodz, Łódzkie

Neuro-Care Sp. z o.o. sp. kom., Katowice, Śląskie

Conditions: Neuropathic Pain, Distal Sensory Polyneuropathy

Learn More ›

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

NCT06672939

Recruiting

The main purpose of this study, performed under Master Protocol J4M-MC-PWMP, is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the study will last about 18 months.

Gender:

ALL

Ages:

Between 12 years and 17 years

Trial Updated:

06/24/2025

Locations: Carey Chronis MD Pediatric, Infant and Adolescent Medicine, Ventura, California +39 locations

Carey Chronis MD Pediatric, Infant and Adolescent Medicine, Ventura, California

Yale School of Medicine - Yale Diabetes Center (YDC)) Trials, New Haven, Connecticut

Stamford Therapeutics Consortium, Stamford, Connecticut

Children's Healthcare of Atlanta - Center for Advanced Pediatrics, Atlanta, Georgia

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

Velocity Clinical Research, Lafayette, Louisiana

MedPharmics, LLC, Gulfport, Mississippi

Sundance Clinical Research, Saint Louis, Missouri

Lucas Research, Inc., Morehead City, North Carolina

Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania

Vanderbilt Health One Hundred Oaks, Nashville, Tennessee

Dynamed Clinical Research, LP d/b/a DM Clinical Research, Houston, Texas

La Providence Pediatrics Clinic - Chemidox Clinical Trials, Houston, Texas

Martin Diagnostic Clinic, Tomball, Texas

Velocity Clinical Research, Salt Lake City, South Jordan, Utah

L2IP - Instituto de Pesquisas Clínicas, Brasília, Distrito Federal

Hospital Universitario de Caxias do Sul, Caxias do Sul, Rio Grande Do Sul

CPQuali Pesquisa Clínica, Sao Paulo, Not set

Sheba Medical Center, Ramat Gan, HaMerkaz

Shaare Zedek Medical Center, Jerusalem, Yerushalayim

Shamir Medical Center, Beer Jacob, Not set

Azienda Ospedaliero Universitaria Meyer, Firenze, Toscana

Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento, Verona, Veneto

Azienda Ospedaliero Universitaria Maggiore della Carità, Novara, Not set

Ospedale Pediatrico Bambino Gesù, Roma, Not set

Shikoku Medical Center for Children and Adults, Zentsuji, Kagawa

Saitama Medical University Hospital, Iruma-Gun, Saitama

Osaka City General Hospital, Osaka, Not set

Sagaekiminami Clinic, Saga-shi, Not set

Krakowskie Centrum Medyczne - FutureMeds, Kraków, Not set

Instytut Diabetologii - Warsaw, Warsow, Not set

FutureMeds - Targowek, Warszawa, Not set

FutureMeds sp. z o. o., Wroclaw, Not set

Bristol Royal Hospital for Children, Bristol, Bristol, City Of

Addenbrookes Hospital, Cambridge, Cambridgeshire

Hull Royal Infirmary, Hull, East Riding Of Yorkshire

Northwick Park Hospital, Harrow, Middlesex

Ninewells Hospital, Dundee, Scotland

Barnsley Hospital NHS Foundation Trust, Barnsley, Not set

Alder Hey Children's Hospital, Liverpool, Not set

Conditions: Obesity, Overweight

Learn More ›

A Study of Ivonescimab in People With Endometrial and Cervical Cancers

NCT06925724

Recruiting

The researchers are doing this study to find out if ivonescimab is an effective treatment for people with endometrial cancer (EC) and/or cervical cancer (CC). The researchers will also look at whether the study drug is safe and causes few or mild side effects in participants.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/24/2025

Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey +6 locations

Conditions: Endometrial Cancer, Cervical Cancer

Learn More ›

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

NCT00044304

Recruiting

The purpose of this study is to evaluate the safety and efficacy of the tyrosine kinase inhibitor, imatinib mesylate (Gleevec ) in reducing peripheral blood eosinophilia in patients with the myeloid form of hypereosinophilic syndrome (HES). Patients with the hypereosinophilic syndrome who meet a set of criteria designed to select patients with the myeloid form of the disease, as well as patients without myeloid disease who are refractory to standard therapy for HES, will be admitted on this protocol. A thorough clinical evaluation will be performed with emphasis on potential sequelae of eosinophil-mediated tissue damage. A baseline bone marrow will be obtained to exclude leukemia or lymphoma and to assess the degree and nature of eosinophilopoiesis. Bone marrow, blood cells and/or serum will also be collected to test for the presence of a recently described mutation that is associated with imatinib-responsiveness in HES, and to provide reagents (such as DNA, RNA, and specific antibodies) and for use in the laboratory to address issues related to the mechanism of action of imatinib mesylate in HES. Imatinib mesylate will be initiated at a dose of 400 mg daily, the FDA-approved dose for the treatment of chronic myelogenous leukemia. In patients who demonstrate a complete clinical and hematologic response to imatinib therapy and who do not have life-threatening disease, the dose will be decreased gradually to 100mg daily and then discontinued. In order to minimize bone marrow suppression, other myelosuppressive agents will be tapered and discontinued during the first week of therapy with imatinib mesylate. Complete blood counts will be performed weekly for the first month and biweekly thereafter. Clinical assessments will be performed every three months to assess progression of end organ damage. In patients who demonstrate a complete clinical and hematologic response to imatinib therapy and who do not have life-threatening disease, the dose will be decreased gradually to 100 mg daily and then discontinued. In the event of clinical, hematologic or molecular relapse during the taper, the imatinib dose will be increased to a maximum of 600 mg daily to achieve a second remission. Laboratory monitoring will be performed as above except for molecular monitoring which will be monitored monthly if drug is discontinued or molecular relapse occurs. Once a stable dosing regimen is achieved for greater than or equal to 6 months in subjects who have undergone dose descalation or greater than or equal to 2 years in subjects receiving 300-400 mg of imatinib daily who did not qualify for dose de-escalation, the frequency of NIH visits and end organ assessments will be decreased to 6 months, with molecular monitoring every 3 months and monthly routine laboratory assessments. ... Read Less

Gender:

ALL

Ages:

2 years and above

Trial Updated:

06/24/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Eosinophilic Myeloid Neoplasm, Hypereosinophilic Syndrome

Learn More ›

Collection of Tissue Samples for Cancer Research

NCT00900198

Recruiting

Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: * To obtain samples from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment. * To obtain samples for research purposes from non-surgical procedures, such as percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Eligibility: -Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of age) who are being evaluated for and/or treated for cancer at the NIH Clinical Center participating sites. Design: * This is a multicenter tissue procurement protocol with NCI as the coordinating center. * For adult patients: specimens for research purposes, as outlined in this protocol, will be obtained from tests and procedures that are done as required by the primary research protocols to which a patient is enrolled or as part of their standard-of-care treatment. Non-surgical procedures, such as percutaneous biopsies, may also be performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Tissues and biological fluids to be procured may include but are not limited to blood, serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial alveolar lavage (BAL), circulating tumor cells, hair follicles, and bone marrow. These specimens will be stored with unique identifiers and used to perform only those research studies that are outlined in this protocol. * For pediatric patients: tumor biopsy/resection tissue used for pediatric preclinical model development will only be from tissue already being obtained as part of a procedure necessary for the patient s clinical care or as part of a primary research protocol; blood specimens will be collected as part of a blood collection already scheduled for the patient s clinical care or as part of the planned pre-procedure bloodwork; volumes collected will not exceed institutional research limits. * Given the risks associated with any invasive procedure, such as tumor biopsy, the procedure will be discussed in detail with the patients and their parents/guardian (as indicated), including the side effects, prior to obtaining a separate consent for each procedure. A separate consent will not be signed prior to obtaining samples by minimally invasive measures, such as venipuncture. * This study has two separate consent forms at the NIH Clinical Center: one for adult patients to donate specimens for ongoing research on assay development and studies of molecular pathways, and one for adult and age-appropriate pediatric patients to donate samples for the generation of preclinical models. The study also has consent form templates for adult and pediatric patients at participating sites to donate specimens to create preclinical models. * Patients may remain on study for the duration of their consent or completion of the planned procedure, whichever comes first. Read Less

Gender:

ALL

Ages:

2 months and above

Trial Updated:

06/24/2025

Locations: UC Davis, Sacramento, California +16 locations

Conditions: Neoplasms, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome

Learn More ›